LeMaitre Vascular Reports Q3 2026 Growth Driven by Strong Graft Demand and Price Increases
LeMaitre Vascular (LMAT) reported strong third-quarter 2026 results, with net sales reaching $68.0 million, an 11% increase year-over-year. Organic sales growth hit 12%, fueled by a combination of a 7% price increase and a 5% rise in unit volume. Key product drivers included a 34% surge in RestoreFlow Allografts sales and 20% growth in the vascular graft portfolio, reflecting robust international demand. The company is currently managing the integration of B. Braun's polyester and silver-coated vascular assets, an acquisition valued at $19.2 million. While this transition introduces some operational complexity and potential back-order risks during manufacturing transfers to their expanded Burlington facility, LeMaitre maintained its full-year 2026 guidance. The company expects annual revenue between $274.8 million and $276.8 million and non-GAAP diluted EPS between $2.77 and $2.82.
Tickers: $LMAT
Topics: Acquisition Gross Margin Net Sales Growth Organic Sales Growth Revenue by Region